February 16, 2024
New publication shows CR9114 protects against avian flu in mice
The ongoing spread of avian flu among animals has increased the urgency of developing products that could prevent infection in the event of an H5N1 pandemic. A new study by Leyden Labs, published in Nature’s Scientific Reports, shows that the CR9114 antibody can protect intranasally at low dosages against H5N1 in vivo. Read it here.
The study found that CR9114, delivered intranasally, fully protected against H5N1 infection in vivo. By contrast, vaccination with the seasonal quadrivalent influenza vaccine with H1, H3, B/Yam and B/Vic antigen, did not cross-protect mice from H5N1 challenge. Furthermore, CR9114 neutralized 10 different strains of H5 influenza in vitro, further confirming its breadth of potential protection.
Broad protection is critical amid pandemic situations, when there’s no way to know in advance which strain will predominate. CR9114 uniquely targets a highly conserved epitope of flu viruses allowing this broadly protective quality. At Leyden Labs, we remain focused on the discovery, optimization, and development of antibodies that can deliver broad and immediate protection to combat respiratory viral threats.
OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS
Leyden Laboratories B.V.
Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
© Leyden Labs, 2023 | Privacy Statement | Design by Ape to Zebra
